Author and Filmmaker's Death Followed Familiar Course

The death this week of author and filmmaker Nora Ephron has brought an outpouring of grief from around the world. Famous for having written films such as When Harry Met Sally, Ephron had been diagnosed with myelodysplastic syndrome (MDS) some time ago and had been receiving treatment.

MDS is actually a large group of similar diseases of the blood and the bone marrow that can be mild or moderate or severe, depending on the individual. It is not uncommon for MDS to develop as a consequence of previous anti-cancer treatment, but oftentimes it develops on its own.

In some instances, as was the case with Ephron, MDS -- which at one time was referred to not as MDS but as pre-leukemia -- can develop into acute myelogenous (or myeloid) leukemia (AML), and at that point the prognosis is typically not good.

AML is an aggressive hematologic cancer that begins in the marrow cells, caused by changes in the cell's DNA.

Treatments for MDS are few and not very effective. The Leukemia & Lymphoma Society is among many groups currently exploring new treatments for this patient population, and they are funding a Phase III trial for rigorsertib (Estybon) developed by Onconova Therapeutics.

Rigorsertib inhibits multiple molecular processes that are crucial in the growth and survival of these cancer cells. Ideally a new MDS treatment would cut down on the need for MDS patients to receive blood transfusions, and ideally the new treatment would make the development to AML less and less likely.

Source: LLS

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap